Kitov Pharma Ltd (NASDAQ:KTOV) traded at $1.12 at last check on Tuesday, Jun 30, making a downturn move of -7.08% on its previous day’s price.

Looking at the stock we see that its previous close was $1.2 and the beta (5Y monthly) reads 2.19 with the day’s price range being $1.0300 – 1.1700. In terms of its 52-week price range, KTOV has a high of $1.44 and a low of $0.22 -. The company’s stock has gained about 154.78% over that past 30 days.

On the other hand, looking at the outlook for the KTOV stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of Hold. Long term indicators on average place the stock in the category of 50% Buy.

Based on estimates by 1 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Kitov Pharma Ltd (KTOV) stock as a Hold, while 1 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.

Let’s briefly compare Kitov (KTOV) stock to its peers. We find that today’s price change of -7.08% and +27.66% over the past 12 months for KTOV competes that of Zoetis Inc Cl A (ZTS), which has seen its stock price rise 2% in the latest trading session and is +16.29% over the last one year. Another of its peers Takeda Pharmaceutical Co. Ltd (TAK) has dropped -1.91% today, and is +2.32% up over the past year, while Grifols S.A. (GRFS) is also down -7.08% yet its price remains in the green at 27.66% over the same period. Zoetis has a P/E ratio of 39.26 compared to Kitov’s 0 and Takeda’s 22.32. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.04% and 0.46%, respectively, in early deals.

Coming back to Kitov Pharma Ltd (NASDAQ:KTOV), we note that the average 3-month trading volume was 27.96 Million, while that of the preceding 10-day period stands at 155.01 Million. Current shares outstanding are 118.36 Million.

According to data from Thomson Reuters, insiders hold 4.67% of the company’s shares while institutions hold 28.19%. The data shows that short shares as of June 14, 2020, stood at 4.76 Million at a short ratio of 0.25. This represents a 4.56% Short interest in Shares outstanding on June 14, 2020. Shares short rose in June from the previous month at 2.56 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock +53.93% up in year-to-date price movement.